We focused on dasatinib, a multikinase inhibitor, with effect against SRC, abl and c‐kit, among other kinases, that is approved in patients with chronic myeloid leukaemia (CML).16 Here, KIT is linked to chronic myelogenous leukemia, BCR-ABL1 positive.